After reading a Wall Street Journal article this morning, I learned that Tysabri proves still potentially problematic for its users. Two MS patients who were using the treatment have contracted PML, or progressive multifocal leukoencephalopathy, and one has been hospitalized. Both patients are members of the European Union, according to the article. Read more about this news story for full details.
For me, the most interesting bit about this article is that the FDA is not expected to make any changes in the drug's availability. After Tysabri's reintroduction to the market after its short hiatus in 2006, the FDA "decided MS patients willing to accept the risks should be able to have access to the drug's potential benefits" according to the Reuters article. It seems their position has not changed since then, even with these new PML developments.
Please share any thoughts of comments, and check out other news stories and information on Tysabri.
Published On: August 01, 2008